- Home
- CVM vs RANI Comparison
CVM vs RANI Comparison
Compare CVM & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVM
- RANI
- Stock Information
- Founded
- CVM 1983
- RANI 2012
- Country
- CVM United States
- RANI United States
- Employees
- CVM N/A
- RANI N/A
- Industry
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- RANI Medicinal Chemicals and Botanical Products
- Sector
- CVM Health Care
- RANI Health Care
- Exchange
- CVM Nasdaq
- RANI Nasdaq
- Market Cap
- CVM 40.1M
- RANI 41.6M
- IPO Year
- CVM 1987
- RANI 2021
- Fundamental
- Price
- CVM $0.40
- RANI $1.31
- Analyst Decision
- CVM
- RANI Strong Buy
- Analyst Count
- CVM 0
- RANI 5
- Target Price
- CVM N/A
- RANI $11.80
- AVG Volume (30 Days)
- CVM 2.0M
- RANI 420.9K
- Earning Date
- CVM 01-13-2025
- RANI 11-14-2024
- Dividend Yield
- CVM N/A
- RANI N/A
- EPS Growth
- CVM N/A
- RANI N/A
- EPS
- CVM N/A
- RANI N/A
- Revenue
- CVM N/A
- RANI N/A
- Revenue This Year
- CVM N/A
- RANI N/A
- Revenue Next Year
- CVM $152.91
- RANI N/A
- P/E Ratio
- CVM N/A
- RANI N/A
- Revenue Growth
- CVM N/A
- RANI N/A
- 52 Week Low
- CVM $0.36
- RANI $1.24
- 52 Week High
- CVM $3.08
- RANI $8.75
- Technical
- Relative Strength Index (RSI)
- CVM 38.00
- RANI 35.89
- Support Level
- CVM $0.37
- RANI $1.24
- Resistance Level
- CVM $0.42
- RANI $1.61
- Average True Range (ATR)
- CVM 0.04
- RANI 0.11
- MACD
- CVM -0.00
- RANI 0.02
- Stochastic Oscillator
- CVM 11.83
- RANI 18.92
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.